隔夜夜盘市场走势 地址：北京市朝阳区朝阳门外大街甲6号万通中心D座20层（100020） 总机：010-8535 6666 资讯早间报 制作日期： 2025/06/13 1. 国际贵金属期货普遍收涨，COMEX 黄金期货涨 1.88%报 3406.40 美元/盎司， COMEX 白银期货涨 0.41%报 36.41 美元/盎司。 2. 国际油价走强，美油主力合约收涨 1.04%，报 68.86 美元/桶；布伦特原油主 力合约涨 0.69%，报 70.25 美元/桶。 3. 伦敦基本金属收盘多数上涨，LME 期铜涨 0.44%报 9690.50 美元/吨，LME 期 铅涨 0.23%报 1992.00 美元/吨。 4. 国内期货主力合约跌多涨少。燃料油涨超 1%，菜油涨近 1%；跌幅方面，纯 碱跌超 2%，丁二烯橡胶、玻璃、烧碱、焦炭、焦煤、纸浆跌超 1%。 5. 美国农产品期货涨跌不一，CBOT 玉米期货涨 0.34%，报 4.385 美元/蒲式耳。 CBOT 小麦期货跌 1.4%，报 5.2675 美元/蒲式耳。CBOT 大豆期货跌 0.71%，报 10.43 美元/蒲式耳。 投资有风险，入市需谨慎。 本公 ...

Core Viewpoint - Kexing Pharmaceutical (688136.SH) plans to sell its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., for 15 million yuan to reduce management costs and improve asset operation efficiency [1][13]. Group 1: Company Performance - Kexing Pharmaceutical's stock price has doubled since the beginning of the year, with a significant increase of 156.50% from 21.86 yuan per share at the end of 2024 to 56.07 yuan on June 4 [6][10]. - The company reported a revenue of 14.07 billion yuan in 2024, an increase of 11.75% year-on-year, and achieved a net profit of 31 million yuan, marking a turnaround from previous losses [10][11]. - Despite the revenue growth, the company's R&D expenses significantly decreased to 168 million yuan in 2024, down 51.30% from the previous year [11][13]. Group 2: Shareholder Actions - The controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., plans to reduce its stake by up to 3%, potentially cashing out over 336 million yuan based on the stock price at the time of the announcement [4][5]. - This is the first time since Kexing Pharmaceutical's IPO that the major shareholder has announced a reduction in holdings, raising market concerns about the intention behind the move [3][5]. Group 3: Market Reactions - Following the announcement of the major shareholder's reduction plan, Kexing Pharmaceutical's stock price fell to 50.95 yuan per share by June 12 [8]. - Market skepticism arose due to the significant stock price increase prior to the reduction announcement, with some investors questioning the motives behind the shareholder's decision [5][6].

Core Viewpoint - The Chinese innovative drug sector is experiencing significant growth, driven by increased policy support, breakthroughs in research and development, and a surge in business development (BD) transactions, indicating a clear trend towards internationalization and positioning China as a "pharmaceutical powerhouse" [1][2][4]. Group 1: Market Performance - The innovative drug sector has seen a remarkable recovery since 2025, with the Wind Innovative Drug Index rising by 27.46% year-to-date, outperforming the broader market [2]. - In the Hong Kong market, the Hang Seng Innovative Drug Index has surged by 73.12%, with notable individual stocks like Sanofi and Kexing Biotech seeing increases of over 100% [2]. - A total of 78 stocks in the A-share market have collectively gained over 400 billion yuan in market value this year [2]. Group 2: Reasons for Growth - The recovery is attributed to three main factors: the innovative drug index's previous decline creating upward potential, the transition of biotech companies to profitability, and a significant increase in China's share of global BD transactions [3][4]. - The share of China's BD transactions in global deals has risen from 5% in 2021 to 42% in 2025, with the total value of BD transactions reaching $41 billion [3]. Group 3: Policy Support - The Chinese government has intensified support for innovative drugs, with initiatives outlined in the 2024 and 2025 government work reports to accelerate the development of innovative drugs and medical devices [5][6]. - The State Council has approved a comprehensive plan to support the entire chain of innovative drug development, focusing on price management, insurance payments, and optimizing approval processes [6]. Group 4: R&D Breakthroughs - Chinese pharmaceutical companies are increasingly focusing on original research, with a significant rise in the number of innovative drugs entering clinical trials [7][8]. - In 2024, China had 704 innovative drugs, leading globally, and accounted for 31.33% of the world's first-in-class (FIC) drugs [8]. Group 5: Business Development Transactions - The total value of BD transactions for Chinese innovative drugs reached a record $523 billion in 2024, with significant deals announced in recent months [11][12]. - Major companies like Sanofi and CSPC have engaged in high-value BD transactions, indicating strong international interest in Chinese biotech assets [11][12].

Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

Market Overview - A-shares opened higher on June 11, with the Shanghai Composite Index surpassing 3400 points during the midday session, ultimately closing up by 0.52% at 3402.32 points [1] - The Shenzhen Component Index rose by 0.83% to 10246.02 points, while the ChiNext Index increased by 1.21% to 2061.87 points [1] - Total trading volume in the Shanghai and Shenzhen markets was 12,555 billion, a decrease of 1,598 billion from the previous trading day [1] Sector Performance - The financial sector led the gains, with significant activity in rare earth permanent magnets, short drama games, automotive parts, solid-state batteries, and digital currency themes [1] - The rare earth sector continued to strengthen, with several stocks hitting the daily limit or rising over 10% [3] - Automotive stocks showed strong performance throughout the day, with multiple stocks also hitting the daily limit or rising over 10% [3] - The pharmaceutical sector experienced a downturn, with several stocks declining over 6% [3] - Communication stocks faced notable declines, with several companies dropping over 5% [3] Investor Sentiment and Market Outlook - Citic Securities noted that investor sentiment in May was generally stable, with expectations of continued market risk appetite due to improved US-China trade relations [5] - Zhongyuan Securities indicated that the market's liquidity remains ample following recent monetary policy adjustments, with expectations for further policy support [6] - Dongguan Securities highlighted the potential for structural opportunities in the market driven by positive economic indicators and technological breakthroughs [7] - Shenwan Hongyuan suggested that the market may remain in a consolidation phase, with a focus on key economic data and policy developments in June [8]

大家好！来一起关注上午的市场行情和最新资讯～ 6月11日上午，A股市场盘中冲高，午前涨幅有所回落。截至午间收盘，上证指数涨0.54%，收于3403 点；深证成指涨0.89%，创业板指涨1.29%。 | A股 港股 美股 全球 基金 商品三 | | | --- | --- | | 内地股票 △ | | | 行情 涨跌分布 | 资金净流入 | | 上证指数 北证50 | 深证成指 | | 3403.00 1426.22 | 10252.69 | | +18.18 +0.54% +90.50 +0.89% -1.70 -0.12% | | | 科创50 万得全A | 创业板指 | | 984.39 5195.72 | 2063.49 | | +1.48 +0.15% +26.22 +1.29% +35.92 +0.70% | | | 沪深300 中证A500 | 中证500 | | 3897.35 | 5798.60 4572.77 | | +31.88 +0.82% +40.61 +0.71% +36.72 +0.81% | | | 中证红利 中证1000 | 深证100 | | 6192.45 5472.30 ...

Group 1 - Kexing Pharmaceutical plans to transfer 100% equity of its wholly-owned subsidiary Shenzhen Tong'an Pharmaceutical Co., Ltd. for 15 million yuan, as the subsidiary has not conducted business in recent years and holds 20 drug approval numbers [1] - The sale aligns with Kexing's strategy to focus on the biopharmaceutical sector, enhancing core competitiveness and reducing operational risks, which is expected to increase profit and cash flow in 2025 [1] Group 2 - Renfu Pharmaceutical announced the resignation of three executives, including the president and vice president, due to personal reasons, which may raise concerns about management stability and strategic execution in the short term [2] - The new president, Du Wentao, is an internal candidate with extensive experience, which may facilitate a smooth transition [2] Group 3 - Lianhuan Pharmaceutical was fined approximately 61.04 million yuan for violating antitrust laws by engaging in a price-fixing agreement with competitors regarding a raw material [3] - The penalty includes the confiscation of illegal gains and a fine, which may impact the company's operational stability and profitability, potentially leading to short-term stock price pressure [3] Group 4 - ST Jingfeng is involved in a significant lawsuit concerning a contractual liability dispute with an amount of 76.98 million yuan at stake, with the court having accepted the case [4] - The lawsuit's outcome remains uncertain, which may affect investor confidence and lead to stock price volatility [4] Group 5 - Zhongsheng Pharmaceutical reported abnormal stock trading fluctuations, with a cumulative price deviation exceeding 20% over two trading days [5][6] - The company is conducting Phase III clinical trials for its product RAY1225, but the progress remains uncertain, raising concerns about the sustainability of the high stock price [6]

Meeting Overview - The second meeting of the second supervisory board of the company was held on June 9, 2025, with all three supervisors present [2][3]. Resolution Summary - The supervisory board approved the proposal to transfer 100% equity of its wholly-owned subsidiary, Shenzhen Tong'an Pharmaceutical Co., Ltd., to Guangxi Drug Research Institute Co., Ltd. for a price of 15 million yuan [4][10]. - The board concluded that the transaction would enhance asset operation efficiency and is in line with the company's actual situation, with no harm to shareholders' interests [4][10]. Transaction Details - The transaction does not constitute a related party transaction or a major asset restructuring as defined by regulations, and there are no significant legal obstacles to its implementation [8][10]. - The transfer price of 15 million yuan was agreed upon based on voluntary and fair negotiations [14]. Subsidiary Overview - Shenzhen Tong'an Pharmaceutical has not conducted actual business in recent years and primarily holds approval numbers for 20 pharmaceutical products [13]. - The subsidiary's ownership is clear, with no encumbrances or legal issues affecting the transfer [13]. Financial Impact - The sale of the subsidiary is expected to increase the company's profit and cash flow in 2025, aligning with the company's strategic focus on the biopharmaceutical sector [21].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第二十一 次会议于 2025 年 6 月 9 日以现场的方式召开。会议通知已于 2025 年 6 月 6 日发 出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、监事会会议审议情况 证券代码：688136 证券简称：科兴制药 公告编号：2025-034 科兴生物制药股份有限公司 第二届监事会第二十一次会议决议公告 科兴生物制药股份有限公司监事会 2025 年 6 月 11 日 （一）审议通过《关于转让全资子公司股权的议案》 公司监事会认为：考虑到公司全资子公司深圳同安医药有限公司（以下简称 "同安医药"）近年来未实际开展业务，将公司持有的同安医药 100%的股权作 价 1,500 万元转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研 所"），有助于提高资产运营效率，符合公司的实际情况。本次交易 ...